24/7 Market News Snapshot 29 January, 2025 – TNF Pharmaceuticals, Inc. Common Stock (NASDAQ:TNFA)

January 29, 2025

DENVER, Colo., 29 January, 2025 (247marketnews.com) – (Nasdaq:TNFA) are discussed in this article.
TNF Pharmaceuticals, Inc. (Nasdaq:TNFA) is currently experiencing a notable surge in its stock performance, which has risen approximately 10.1% during today’s trading session, going from a previous close of $1.170 to a current price of $1.288. This positive momentum is accompanied by a trading volume of 675,000 shares, indicating a growing interest among investors. If the stock maintains its performance above the critical support level of $1.25, it could signal further bullish potential as traders monitor key resistance levels for future price targets.

In addition to its stock market activity, TNF Pharmaceuticals has announced the initiation of a pivotal clinical study aimed at investigating isomyosamine, a novel oral TNF-alpha inhibitor. This study is particularly focused on preserving lean muscle mass in patients undergoing treatment with GLP-1 medications for weight loss and chronic weight management. Research highlights a significant risk for these patients, as up to 40% of the total weight lost may come from lean body mass, raising concerns about muscle preservation.

The initial phase of this study will examine individuals treated with GLP-1 agonists like Wegovy® and Ozempic®, particularly those who show elevated inflammation associated with sarcopenia, a condition characterized by age-related muscle deterioration. By targeting the inflammatory effects of TNF-alpha, isomyosamine aims to mitigate muscle loss in these patients.

Mitchell Glass, M.D., President and Chief Medical Officer of TNF, emphasized the importance of these studies in understanding isomyosamine’s potential benefits, while David Jacobs, CEO of Renova Health, expressed excitement about the collaboration to enhance patient selection and site identification for the clinical trials. With the GLP-1 receptor agonist market projected to reach $105 billion by 2029, TNF Pharmaceuticals is poised to make significant contributions to improving outcomes for patients affected by autoimmune and inflammatory conditions.

Related news for (TNFA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.